Keywords:
Cardiac, CT, Contrast agent-intravenous, Metabolic disorders
Authors:
C. I. Mihalache1, J. Mayer2, T. Damy3, A. Luciani2, H. Kobeiter2, A. Rahmouni2, J. F. Deux4; 1Meaux/FR, 2Creteil/FR, 3Paris/FR, 4Cedex/FR
Methods and Materials
Patients
Thirteen consecutive patients with CA and 11 control patients were included in this prospective study.
Regarding the type of amyloidosis,
6 patients had a Transthyretin Familial Amyloidosis (FAP ATTR),
5 patients had AL amyloidosis and 2 patients had a senile systemic amyloidosis.
All patients with CA had a thickening of cardiac wall (> 12 mm for left ventricle) on cardiac MRI associated with a diffuse myocardial enhancement on late gadolinium enhancement (LGE).
Sixty one percent of patients (8/13) had also a positive endomyocardial biopsy for amyloidosis.
MDCT Examination
All subjects were scanned with a 64-detector MDCT with a first pass and a delayed acquisition performed 5 minutes after injection of 1.5 mg/Kg of contrast medium. MDCT was performed 3 +/- 2 days after cardiac MRI using a 64-detector CT in all patients with CA.
Image analysis
Mean myocardial attenuation of left ventricle,
myocardial signal-to-noise ratio (SNR myoc),
blood pool SNR (SNR blood),
contrast-to-noise ratio (CNR) between blood pool and myocardium (CNR blood-myoc) and relative attenuation index (RAI) defined as variation of myocardial attenuation between delayed and first pass acquisitions were calculated on first pass and delayed images for both groups.
Data are expressed as mean ± standard deviation.
A non parametric test was used to compare groups.